Evidence map›Paper›PMID 27092244›Full record

ReviewF1000Research2016

Cell biology and genetics of minimal change disease.

Moin A Saleem, Yasuko Kobayashi

Open access · goldAbstract readReview
In one paragraph

Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Anti-Tumor Necrosis Factor Treatment for Glomerulopathy: Case Report and Review of Literature.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2024
    Article
  7. Article
  8. Article
  9. Minimal Change Disease in an Adult: A Case Report.JNMA; journal of the Nepal Medical Association · 2022
    Article
  10. Article
  11. Review
  12. The important roles and molecular mechanisms of annexin AAnnals of translational medicine · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Interleukin-18 binding protein attenuates renal injury of adriamycin-induced mouse nephropathy.International journal of clinical and experimental pathology · 2019
    Article
  17. Article
  18. Article
  19. Genetics of childhood steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2017
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Moin A SaleemPaediatric Renal Medicine, University of Bristol, Bristol, UK; Children's Renal Unit, Bristol Royal Hospital for Children, Bristol, UK.
Yasuko KobayashiPaediatric Renal Medicine, University of Bristol, Bristol, UK; Department of Pediatrics, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Bristol Royal Hospital for Children · GBGunma University · JP

Funding

Medical Research Council G0800571Medical Research Council MR/L002418/1
6 · The paper itself

Abstract

Minimal change disease (MCD) is an important cause of nephrotic syndrome and is characterized by massive proteinuria and hypoalbuminemia, resulting in edema and hypercholesterolemia. The podocyte plays a key role in filtration and its disruption results in a dramatic loss of function leading to proteinuria. Immunologic disturbance has been suggested in the pathogenesis of MCD. Because of its clinical features, such as recurrent relapse/remission course, steroid response in most patients, and rare familial cases, a genetic defect has been thought to be less likely in MCD. Recent progress in whole-exome sequencing reveals pathogenic mutations in familial cases in steroid-sensitive nephrotic syndrome (SSNS) and sheds light on possible mechanisms and key molecules in podocytes in MCD. On the other hand, in the majority of cases, the existence of circulating permeability factors has been implicated along with T lymphocyte dysfunction. Observations of benefit with rituximab added B cell involvement to the disease. Animal models are unsatisfactory, and the humanized mouse may be a good model that well reflects MCD pathophysiology to investigate suggested "T cell dysfunction" directly related to podocytes in vivo. Several candidate circulating factors and their effects on podocytes have been proposed but are still not sufficient to explain whole mechanisms and clinical features in MCD. Another circulating factor disease is focal segmental glomerulosclerosis (FSGS), and it is not clear if this is a distinct entity, or on the same spectrum, implicating the same circulating factor(s). These patients are mostly steroid resistant and often have a rapid relapse after transplantation. In clinical practice, predicting relapse or disease activity and response to steroids is important and is an area where novel biomarkers can be developed based on our growing knowledge of podocyte signaling pathways. In this review, we discuss recent findings in genetics and podocyte biology in MCD.

Indexed as

circulating factorfocal segmental glomerulosclerosisMinimal change diseasepermeabilitypodocytesteroid-resistant nephrotic syndromesteroid-sensitive nephrotic syndrome

Identifiers

PMID27092244
PMCPMC4821284
OpenAlexW2334736175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.